CRMD cites diversified specialty pharma platform and new market opportunities
CRMD says it has evolved into a diversified specialty pharma with eight marketed products and a scalable institutional platform, citing reimbursement transition, Medicare Advantage focus, REZZAYO expansion potential, and robust financials for further growth.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.